UBS Group AG - 31 Dec 2024 SCHEDULE 13G/A Report for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX)

Filing Manager
UBS Group AG
Reporting Manager
UBS Group AG
Security
Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share
Symbol
AMRX
Disclosed Ownership
0 shares
Ownership
0%
Form type
SCHEDULE 13G/A
Filing time
10 Feb 2025, 08:59:12 UTC
Date of event
31 Dec 2024
Previous filing
30 Oct 2024
SEC
View on sec.gov

Quoteable Key Fact

"UBS Group AG disclosed 0% ownership in Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX) on 31 Dec 2024."

Quick Takeaways

  • UBS Group AG filed SCHEDULE 13G/A for Amneal Pharmaceuticals, Inc. Class A Common Stock, par value $0.01 per share (AMRX).
  • Disclosed ownership: 0%.
  • Date of event: 31 Dec 2024.

What Changed

  • Previous schedule filing date: 30 Oct 2024.
  • Current filing was accepted on 10 Feb 2025, 08:59.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
UBS Group AG 0% 0 0 0 Andrew Johnson Director
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .